DalsnaFinance

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Stocks The Motley Fool By The Motley Fool 31 Jul 2026 19:33 1 min read
Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?  The Motley Fool

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock? The Motley Fool

Read the full story on The Motley Fool → Opens the original article on news.google.com

Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.